Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HRS-5041 in Healthy Male Volunteers
NCT06559007Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS-5041 in prostate cancer (PCa) (2 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Maximum Plasma Concentration at Day 10, Area Under the Curve to Last Timepoint at Day 10 and 5 more. Started Sep 2024; status: completed.
02
Drugs
HRS-5041
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06559007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559007.